Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 295-299

  Gao, Jian Zhi ^a,b   Du, Jing Li ^a,c   Wang, Yong Ling ^b   Li, Jia ^a   Wei, Li Xin ^a   Guo, Ming Zhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c Department of Pathology   (China)

Author keywords

Curcumin; Hepatocellular carcinoma; K ras; Signaling pathway; Vascular endothelial growth factor; Vascular endothelial growth factor blocker

Indexed keywords

BEVACIZUMAB; CURCUMIN; DIETHYLNITROSAMINE; K RAS PROTEIN; MESSENGER RNA; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; LIVER CELL CARCINOMA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84911458443     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2694     Document Type: Article

References (35)

1. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE and Rimbach G: Curcumin - from molecule to biological function. Angew Chem Int Ed Engl 51: 5308-5332, 2012.
2. Bauer AL, Jackson TL, Jiang Y and Rohlf T: Receptor cross-talk in angiogenesis: mapping environmental cues to cell phenotype using a stochastic, Boolean signaling network model. J Theor Biol 264: 838-846, 2010.
3. Jiang JT, Zhang LF, Zhou B, Zhang SQ, Li SM, Zhang W, Zhang J, Qiao Z, Kong RR, Ma YF and Chen S: Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis. Asian Pac J Cancer Prev 13: 3379-3383, 2012.
4. Sun P, Yu H, Zhang WQ, Hu M and Lv R: Lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo.Oncol Rep 28: 1687-1692, 2012.
5. Meng QW, Li Y, Hu BS, Shao PJ, Zhan MX, Yu XY and Lu LG: Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Zhonghua Yi Xue Za Zhi 93: 341-4, 2013 (In Chinese).
6. Zhao X, Li J, Zhuo J and Cai L: Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma. Biochem Biophys Res Commun 403: 417-421, 2010.
7. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology 58: 642-653, 2013.
8. Miuma S, Ichikawa T, Arima K, Takeshita S, Muraoka T, Matsuzaki T, Ootani M, Shibata H, Akiyama M, Ozawa E, et al: Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. J Cell Biochem 113: 3113-3121, 2012.
9. Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, et al: Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19: 3681-3692, 2013.
10. Inoue S, Hartman A, Branch CD, Bucana CD, Bekele BN, Stephens LC, Chada S and Ramesh R: mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory affect on lung tumor xenograft. Mol Ther 15: 287-294, 2007.
11. Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C and Cheng AL: Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 85: 44-52, 2013.
12. Futakuchi M, Hirose M, Ogiso T, Kato K, Sano M, Ogawa K and Shirai T: Establishment of an in vivo highly metastatic rat hepatocellular carcinoma model. Jpn J Cancer Res 90: 1196-1202, 1999.
13. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A and Popescu I: Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 17: 411-417, 2008.
14. Zhao K, Song X, Huang Y, Yao J, Zhou M, Li Z, You Q, Guo Q, and Lu N: Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling. Eur J Pharmacol 737: 57-69, 2014.
15. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, et al: Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 41: 97-103, 2004.
16. Lee J, Choi KJ, Lim MJ, Hong F, Choi TG, Tak E, Lee S, Kim YJ, Chang SG, Cho JM, et al: Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase. Cell Res 20: 919-934, 2010.
17. Lee JE, Cranna NJ, Chahal AS and Quinn LM: Genetic systems to investigate regulation of oncogenes and tumour suppressor genes in Drosophila. Cells 1: 1182-1196, 2012.
18. Mateus AR, Simões-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G, Luber B and Seruca R: E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 315: 1393-1402, 2009.
19. Rak J and Yu JL: Oncogenes and tumor angiogenesis: the question of vascular “supply” and vascular “demand”. Semin Cancer Biol 14: 93-104, 2004.
20. Cornellà H, Alsinet C and Villanueva A: Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 35: 821-825, 2011.
21. Heberlein A, Muschler M, Lenz B, Frieling H, Büchl C, Gröschl M, Riera R, Kornhuber J, Bleich S and Hillemacher T: Serum levels of vascular endothelial growth factor A increase during alcohol withdrawal. Addict Biol 15: 362-364, 2010.
22. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW and Su IJ: Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis.Hepatology 49: 1962-1971, 2009.
23. Aravalli RN, Steer CJ and Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063, 2008.
24. Berasain C, Nicou A, Garcia-Irigoyen O, Latasa MU, Urtasun R, Elizalde M, Salis F, Perugorría MJ, Prieto J, Recio JA, Corrales FJ and Avila MA: Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism. Dig Dis 30: 524-531, 2012.
25. Overmeyer JH and Maltese WA: Death pathways triggered by activated Ras in cancer cells. Front Biosci (Landmark Ed) 16: 1693-1713, 2011.
26. Ehrkamp A, Herrmann C, Stoll R and Heumann R: Ras and rheb signaling in survival and cell death. Cancers (Basel) 5: 639-661, 2013.
27. Chen X, Lin YN, Fang DH, Zhang HQ and Huang WJ: Effect of crucumin on vascular endothelial function in atherosclerotic rabbits. Zhongguo Zhong Yao Za Zhi 38: 3343-3347, 2013 (In Chinese).
28. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, Wu X, Cheng L, Ma C, Xia J and Wang Z: Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett 231: 82-91, 2014.
29. Almanaa TN, Geusz ME and Jamasbi RJ: A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer 4: 536-548, 2013.
30. Johnson JJ and Mukhtar H: Curcumin for chemoprevention of colon cancer. Cancer Lett 255: 170-181, 2007.
31. Chen WC, Lai YA, Lin YC, Ma JW, Huang LF, Yang NS, Ho CT, Kuo SC and Way TD: Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 61: 11817-11824, 2013.
32. Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX and Zhao YF: Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol 79: 106-118, 2011.
33. Pantazis P, Varman A, Simpson-Durand C, Thorpe J, Ramalingam S, Subramaniam D, Houchen C, Ihnat M, Anant S and Ramanujam RP: Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo. Altern Ther Health Med 16: 12-14, 2010
34. Wang M, Ruan Y, Chen Q, Li S, Wang Q and Cai J: Curcumin induced HepG2 cell apoptosis-associated mitochondrial membrane potential and intracellular free Ca(2+) concentration. Eur J Pharmacol 650: 41-47, 2011.
35. Ranjan AP, Mukerjee A, Helson L, Gupta R and Vishwanatha JK: Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis.Anticancer Res 33: 3603-3609, 2013.